Home » Stocks » NBIX

Neurocrine Biosciences, Inc. (NBIX)

Stock Price: $109.51 USD 2.70 (2.53%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $109.52 +0.01 (0.01%) Feb 26, 4:31 PM
Market Cap 10.29B
Revenue (ttm) 1.05B
Net Income (ttm) 407.30M
Shares Out 93.10M
EPS (ttm) 4.16
PE Ratio 26.32
Forward PE 35.71
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $109.51
Previous Close $106.81
Change ($) 2.70
Change (%) 2.53%
Day's Open 108.00
Day's Range 105.58 - 110.58
Day's Volume 1,292,558
52-Week Range 72.14 - 136.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 weeks ago

Neurocrine (NBIX) delivered earnings and revenue surprises of 506.78% and -4.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 weeks ago

Shares of Neurocrine Biosciences (NASDAQ:NBIX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 13.33% year over year to $0.91...

PRNewsWire - 3 weeks ago

SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2020 and provi...

Zacks Investment Research - 1 month ago

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 1 month ago

SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq mar...

Forbes - 1 month ago

Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and improving fundamentals over the last few years but have underperformed in...

Other stocks mentioned: IONS, VERX
PRNewsWire - 1 month ago

SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product and inventory adjust...

PRNewsWire - 1 month ago

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 1...

24/7 Wall Street - 2 months ago

After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.

Other stocks mentioned: ACAD, QURE, VRTX, ZGNX
Forbes - 2 months ago

Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, has more room for growth in the near term. NBIX stock is...

Seeking Alpha - 3 months ago

Neurocrine Biosciences reported disappointing sales of Ingrezza, as disruptions to clinical practice caused by COVID-19 have impacted new prescriptions, refills, and patient compliance. If COV...

Seeking Alpha - 3 months ago

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Neurocrine (NBIX) delivered earnings and revenue surprises of -663.64% and -8.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 months ago

Shares of Neurocrine Biosciences (NASDAQ:NBIX) decreased 13.34% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.78% year over year...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2020 and provided revised fu...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: K...

Insider Monkey - 3 months ago

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...

Forbes - 3 months ago

Our indicative theme of Out Of Favor Healthcare Stocks Poised For Gains is down by about -13% year-to-date, compared to the S&P 500 which is up by about 2% over the same period. This theme inc...

Other stocks mentioned: VRTX
Zacks Investment Research - 3 months ago

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 3 months ago

Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.

InvestorPlace - 4 months ago

Investors seeking strong growth companies to invest in should watch Credit Acceptance Corporation, RenaissanceRe and Neurocrine Biosciences. The post 3 Companies to Invest In for Mammoth Growt...

Other stocks mentioned: CACC, RNR
Forbes - 4 months ago

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma co...

Other stocks mentioned: ALKS, ACAD, ARWR, BMRN, IONS
24/7 Wall Street - 4 months ago

With earnings season about to kick off, investors are being forced into a different sort of earnings season.

Other stocks mentioned: ALXN, AMGN, GILD
PRNewsWire - 4 months ago

SAN DIEGO and BOSTON, Oct. 7, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Boston-based Me2/Orchestra, the world's only known classical music organization created for p...

PRNewsWire - 4 months ago

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday...

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyses evaluating the efficacy and safety of ONGENTYS® (opicapone) ...

Seeking Alpha - 5 months ago

Ongentys, an add-on treatment for patients with Parkinson's disease, is entering the market soon.

Seeking Alpha - 5 months ago

Neurocrine Presents Data, And Other News: The Good, Bad And Ugly Of Biopharma

Seeking Alpha - 5 months ago

Neurocrine Looks Like A Long-Term Value After Share Price Decline

Seeking Alpha - 5 months ago

New Data Support The Idea That Neurocrine Biosciences Is Building A Credible Parkinson's Portfolio

The Motley Fool - 5 months ago

The much-anticipated launch of Ongentys has arrived.

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.

The Motley Fool - 5 months ago

Three years after treatment with NBIb-1817, Parkinson's disease patients still are still showing improvements.

Other stocks mentioned: VYGR
PRNewsWire - 5 months ago

SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.

Seeking Alpha - 6 months ago

Ingrezza Remains Surprisingly Strong For Neurocrine

The Motley Fool - 6 months ago

The biotech blew past Wall Street estimates with soaring sales of Ingrezza.

Seeking Alpha - 6 months ago

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Neurocrine (NBIX) delivered earnings and revenue surprises of 24.62% and 18.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Investors Business Daily - 6 months ago

Late Monday, Neurocrine Biosciences reported second-quarter earnings that doubled the year-earlier figure, shattering analyst expectations and sending shares of NBIX stock higher after hours. ...

Zacks Investment Research - 7 months ago

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

These frontrunners are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of the opportunity.

Other stocks mentioned: DPZ, MKTX
CNBC - 7 months ago

Health-care stocks keep hitting highs. Mark Newton of Newton Advisors and Danielle Shay of Simpler Trading share their favorite names.

Other stocks mentioned: PKI, XLV
PRNewsWire - 7 months ago

SAN DIEGO, July 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Mond...

Seeking Alpha - 8 months ago

Neurocrine Further Expands Its Pipeline With An Early-Stage Deal

GuruFocus - 8 months ago

During a May 6 earnings conference call, the head of business development and strategy for Neurocrine Biosciences Inc (NASDAQ:NBIX) said the company was looking for other partnerships, similar...

Other stocks mentioned: TAK
24/7 Wall Street - 8 months ago

The 2020 year is practically halfway done, and this has really been the year of the biotech.

Other stocks mentioned: ACAD, BIIB, BTAI, CRTX, ITCI, SAGE, ZYNE
Seeking Alpha - 8 months ago

Neurocrine's full Phase II data presentation on crinecerfont in adult patients with CAH didn't have many surprises, but the positive efficacy and safety data were welcome.

About NBIX

Neurocrine Biosciences, a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treat... [Read more...]

Industry
Biotechnology
IPO Date
May 23, 1996
CEO
Kevin Gorman
Employees
845
Stock Exchange
NASDAQ
Ticker Symbol
NBIX
Full Company Profile

Financial Performance

In 2020, NBIX's revenue was $1.05 billion, an increase of 32.71% compared to the previous year's $788.10 million. Earnings were $407.30 million, an increase of 1,000.81%.

Financial Statements

Analyst Forecasts

According to 25 analysts, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is 129.00, which is an increase of 17.80% from the latest price.

Price Target
$129.00
(17.80% upside)
Analyst Consensus: Buy